PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.82%
R&D growth above 1.5x AXSM's 10.62%. Michael Burry would check for spending discipline.
-14.04%
G&A reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.04%
Operating expenses growth 1.25-1.5x AXSM's 6.62%. Martin Whitman would scrutinize control.
9.04%
Similar total costs growth to AXSM's 8.31%. Walter Schloss would investigate norms.
104.89%
Interest expense growth above 1.5x AXSM's 24.56%. Michael Burry would check for over-leverage.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-9.04%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
114.37%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
48.96%
Pre-tax income growth exceeding 1.5x AXSM's 17.64%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
135.99%
Tax expense change of 135.99% while AXSM maintains burden. Bruce Berkowitz would investigate strategy.
48.96%
Net income growth exceeding 1.5x AXSM's 19.26%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
53.59%
EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
51.99%
Diluted EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
10.21%
Share count reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.
6.42%
Diluted share reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.